Echo Therapeutics terminates its $20 million at-the-market offering

Company cancels MLV offering due to shareholder feedback and concerns

By Devika Patel

Knoxville, Tenn., May 21 - Echo Therapeutics, Inc. terminated a $20 million at-the-market issuance sales agreement with MLV & Co. LLC on May 18, according to an 8-K filed Monday with the Securities and Exchange Commission. The offering was reported on May 9 and was terminated as of May 28.

The offering was terminated in response to shareholder feedback and concerns.

Franklin, Mass.-based Echo Therapeutics is a dual platform-enabled specialty therapeutics and diagnostics company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.